MedTrace Logo

Ilaris NIS in Korea

NCT06838143 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2026-05-19

No results posted yet for this study

Summary

This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes, Cryopyrin-associated periodic syndromes (CAPS), colchicine resistance familial Mediterranean fever (crFMF), TNF receptor associated periodic syndrome (TRAPS), Hyper-IgD syndrome / Mevalonate kinase deficiency (HIDS/MKD) or Systemic juvenile idiopathic arthritis (sJIA).

Conditions

  • Hereditary Periodic Fever Syndromes
  • Cryopyrin-associated Periodic Syndromes (CAPS)
  • Colchicine Resistance Familial Mediterranean Fever (crFMF)
  • TNF Receptor Associated Periodic Syndrome (TRAPS)
  • Hyper-IgD Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD)
  • Systemic Juvenile Idiopathic Arthritis (sJIA)

Interventions

BIOLOGICAL

Ilaris

Prospective observational study. There is no treatment allocation.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
2 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-29
Primary Completion
2028-09-30
Completion
2028-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06838143 on ClinicalTrials.gov